Bone marrow transplantation (BMT) is nowadays used in various hematological disorders including leukemias. Hemophilia A is sex linked bleeding disorder in which there are various genetic abnormalities in factor VIII gene. Among various hematological disorders, bleeding disorders mainly hemophilia in now widely treated using plasma derived and recombinant factor VIII concentrates. The aim of current review was to determine current role of BMT in treatment of hemophilia and to evaluate current usage of BMT for treatment of hemophilia. Bone marrow transplantation (BMT) is an ideal cure for some cancers, inborn errors of metabolism or immune system . New insights and attractions have been absorbed to novel therapeutic options including gene therapy and BMT to overcoming current problem using manipulation of hematopoietic stem cells. The experiences on BMT in mouse model have been more informative than other struggles. The surveys confirmed while endothelial cells are potent source of factor VIII, transplanted bone marrow does not generate endothelial cells and macrophages. At the best of our knowledge, BMT experiences in patients with hemophilia A limited to four cases . Allogenic BMT has applied for two cases with concurrent diseases. It seems there is lingering way to establish BMT as a common treatment option for patients with hemophilia. Now we need to complete our knowledge and strength our ideas with investigation on animal models to find solutions toward setting BMT in hemophilia.
Peer review refers to the work done during the screening of submitted manuscripts and funding applications. This process encourages authors to meet the accepted standards of their discipline and reduces the dissemination of irrelevant findings, unwarranted claims, unacceptable interpretations, and personal views. Publications that have not undergone peer review are likely to be regarded with suspicion by academic scholars and professionals.
Last date updated on September, 2014